Literature DB >> 429553

Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man.

M Pollack, L S Young.   

Abstract

Serum antibodies to exotoxin A and type-specific lipopolysaccharide were measured by passive hemagglutination in 52 patients with Pseudomonas aeruginosa septicemia. Their comparative protective activities were evaluated by relating the titers of each at the onset of bacteremia to subsequent outcome. High acute serum antitoxin and antilipopolysaccharide titers (log2 reciprocal mean titers greater than 5) were associated with survival (76% of 17 with high vs. 46% of 24 with low antitoxin titers, P = 0.05; 85% of 13 with high vs. 48% of 29 with low antilipopolysaccharide titers, P = 0.03). In contrast, neither antibody titer was significantly associated (P less than or equal to 0.05) with patients' age or sex, severity of underlying disease, presence of leukopenia, steroid or immunosuppressive therapy. Despite a correlation between acute titers of the two antibodies (r = 0.33, P = 0.06), they appeared to protect independently and additively. Whereas 75% of 8 patients with high antitoxin titers and only 38% of 16 with low titers survived with low antilipopolysaccharide titers (P = 0.10), 100% (6/6), 73% (8/11), and 38% (6/16) survived, respectively, when both, one, or neither antibody was present in high titer (P = 0.01). Furthermore, the association between high acute serum antitoxin titers and survival was more pronounced in patients with rapidly fatal underlying disease (P = 0.06) and leukopenia (P = 0.12) than in more favorable prognostic and immune categories. These data indicate that serum antibodies to exotoxin A and lipopolysaccharide are found in most patients with P. aeruginosa septicemia and both are protective. Both antibodies may have therapeutic or prophylactic potential, whereas serum antiexotoxin A antibodies may be particularly beneficial in compromised hosts.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 429553      PMCID: PMC371950          DOI: 10.1172/JCI109300

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  35 in total

1.  Purification of Pseudomonas aeruginosa exotoxin by affinity chromatography.

Authors:  N S Taylor; M Pollack
Journal:  Infect Immun       Date:  1978-01       Impact factor: 3.441

2.  Passive protection by antitoxin in experimental Pseudomonas aeruginosa burn infections.

Authors:  O R Pavlovskis; M Pollack; L T Callahan; B H Iglewski
Journal:  Infect Immun       Date:  1977-12       Impact factor: 3.441

3.  Enzymatically active peptide from the adenosine diphosphate-ribosylating toxin of Pseudomonas aeruginosa.

Authors:  D W Chung; R J Collier
Journal:  Infect Immun       Date:  1977-06       Impact factor: 3.441

4.  Large-scale purification and characterization of the exotoxin of Pseudomonas aeruginosa.

Authors:  S H Leppla
Journal:  Infect Immun       Date:  1976-10       Impact factor: 3.441

5.  Mechanism of action of Pseudomonas aeruginosa exotoxin A in experimental mouse infections: adenosine diphosphate ribosylation of elongation factor 2.

Authors:  O R Pavlovskis; B H Iglewski; M Pollack
Journal:  Infect Immun       Date:  1978-01       Impact factor: 3.441

6.  Structure-activity relationships of an exotoxin of Pseudomonas aeruginosa.

Authors:  M L Vasil; D Kabat; B H Iglewski
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

7.  Experimental studies on the pathogenesis of infections due to Pseudomonas aeruginosa: direct evidence for toxin production during Pseudomonas infection of burned skin tissues.

Authors:  C B Saelinger; K Snell; I A Holder
Journal:  J Infect Dis       Date:  1977-10       Impact factor: 5.226

8.  Toxicity of Pseudomonas aeruginosa exotoxin A for human macrophages.

Authors:  M Pollack; S E Anderson
Journal:  Infect Immun       Date:  1978-03       Impact factor: 3.441

9.  Incidence of exotoxin production by Pseudomonas species.

Authors:  M J Bjorn; M L Vasil; J C Sadoff; B H Iglewski
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

10.  Response of cultured mammalian cells to the exotoxins of Pseudomonas aeruginosa and Corynebacterium diphtheriae: differential cytotoxicity.

Authors:  J L Middlebrook; R B Dorland
Journal:  Can J Microbiol       Date:  1977-02       Impact factor: 2.419

View more
  64 in total

1.  Immunochemical and biochemical analysis of the polyvalent Pseudomonas aeruginosa vaccine PEV.

Authors:  S MacIntyre; T McVeigh; P Owen
Journal:  Infect Immun       Date:  1986-02       Impact factor: 3.441

2.  [Use of pseudomonas immunoglobulin in ventilated patients at an interdisciplinary surgical intensive care station].

Authors:  I Class; W Junginger; T Klöss
Journal:  Infection       Date:  1987       Impact factor: 3.553

Review 3.  Mechanisms in acute septic cardiomyopathy: evidence from isolated myocytes.

Authors:  K Werdan; U Müller; C Reithmann; A Pfeifer; S Hallström; B Koidl; G Schlag
Journal:  Basic Res Cardiol       Date:  1991 Sep-Oct       Impact factor: 17.165

4.  Functionally active monoclonal antibody that recognizes an epitope on the O side chain of Pseudomonas aeruginosa immunotype-1 lipopolysaccharide.

Authors:  B J Stoll; M Pollack; L S Young; N Koles; R Gascon; G B Pier
Journal:  Infect Immun       Date:  1986-09       Impact factor: 3.441

5.  Mapping of the T-cell recognition sites of Pseudomonas aeruginosa PAK polar pili.

Authors:  W Smart; P A Sastry; W Paranchych; B Singh
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

6.  Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.

Authors:  I Eichler; L Joris; Y P Hsu; J Van Wye; R Bram; R Moss
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

7.  Effect of Pseudomonas aeruginosa cytotoxin on thymidine incorporation by murine splenocytes.

Authors:  T G Obrig; A L Baltch; T P Moran; S P Mudzinski; R P Smith; F Lutz
Journal:  Infect Immun       Date:  1984-09       Impact factor: 3.441

8.  Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection.

Authors:  H K Johansen; F Espersen; S J Cryz; H P Hougen; A Fomsgaard; J Rygaard; N Høiby
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

9.  Functional properties of isotype-switched immunoglobulin M (IgM) and IgG monoclonal antibodies to Pseudomonas aeruginosa lipopolysaccharide.

Authors:  M Pollack; N L Koles; M J Preston; B J Brown; G B Pier
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

10.  Immunochemical characterization of high-molecular-weight polysaccharide from Fisher immunotype 3 Pseudomonas aeruginosa.

Authors:  G B Pier; M Pollack; M Cohen
Journal:  Infect Immun       Date:  1984-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.